LONDON, March 01, 2018 -- The global clinical genomics market will grow at a CAGR of 22.1% during the forecast period to reach USD 1,305.1 million by 2023, primarily driven by “growing significance of early disease detection and prevention, rising insistence for precision medicine, increasing application of genetic testing in oncology, and favourable reimbursement scenario related to genetic testing”, Meticulous Research™ noted in a press release today.
The global clinical genomics market is mainly segmented by test type (diagnostic testing, genetic testing, newborn screening, prenatal testing, preimplantation testing, carrier screening and other tests), software, method (molecular tests, chromosomal tests, biochemical tests), end user (hospitals & clinics, government laboratories & research centers, academics and research institutes and other end users), and geography.
The report notes that, based on methods the molecular tests held the largest share, owing to “the advancement in technology, which helps to detect the single nucleotide resolution with cheaper, faster, and with utmost accuracy by using WGS and WES technologies.”
Request Sample Report: https://www.meticulousresearch.com/request-sample-report/?cp_id=3763
Geographically, the global clinical genomics market is segmented into four major regions, namely North America, Europe, Asia-Pacific, and Rest of World. North America accounted for the major share of this market in 2017, followed by Europe and Asia-Pacific region. The major share of the North American region is mainly attributed to “the high burden of chronic and infectious diseases, increasing R&D expenditure, and various government initiatives”. However, the Asia-Pacific region is projected to grow at fastest CAGR during the forecast period, due to “increasing population, rising prevalence of various diseases, availability of funding, and developing healthcare infrastructures in the region”.
Browse report: https://www.meticulousresearch.com/product/clinical-genomics-market-forecast-2023/
The key players in the clinical genomics market are Quest Diagnostics Incorporated, Eurofins Scientific SE, Illumina, Inc., PerkinElmer, Inc., NeoGenomics Inc., Foundation Medicine, Inc., Rosetta Genomics Ltd., Invitae Corporation, Myriad Genetics, Inc., Natera, Inc., Genomic Health, Inc., OPKO Health, Inc., Centogene AG, Clinical Genomics Pty Ltd., 23andMe, Inc., Iverson Genetic Diagnostics, Inc., Veritas Genetics, Gene by Gene, Ltd., GenomeDx Biosciences, Inc., MedGenome, Strand Life Sciences Pvt. Ltd., Beijing Genomics Institute (BGI), Retrogen, Inc., Personalis, Inc., PathGroup.
Enquire before buying: https://www.meticulousresearch.com/enquire-before-buying/?cp_id=3763
Contact:
Viren Shrivastava
Email: [email protected]
Direct Lines: +1-646-781-8004 (North America)
+44-203-868-8738 (Europe)
+91 744-7780008 (Asia-Pacific)


Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
OpenAI Restricts Astra AI Over Cyberattack Risks
DeepSeek to Raise AI API Prices as Demand for New Models Surges
Nintendo Shares Jump as Switch 2 Sales Boost Earnings
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 



